Direct targeting of STAT3 alone and in combination with immune checkpoint inhibitors to treat solid tumours

Bookmark and Share
Published: 10 Jul 2019
Views: 817
Dr David Tweardy - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr David Tweardy speaks to ecancer at the WIN 2019 Symposium in Paris about a drug program targeting STAT3, a cancer molecule involved in most cancers.

He explains that they began looking at STAT3 25 years ago as it was discovered to be a major master regulator within the cell after coming into contact with interleukin 6, a hormone that circulates upon any injury or illness.

If an injury persists and STAT3 continues to be activated then this can cause cancer.

Dr Tweardy explains that this is why molecules were developed to try and 'turn it off' and that now this is the process of trying to convert this finding into drugs.